Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-129-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0031H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Tissue homogenates, Whole blood

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, the kit is stable until the expiration date (see label on the box)

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.6%

Inter-assay (Run-to-Run)

n = 5,
CV = 10.8%

Spiking Recovery

94.7%

Dilution Linearity

93.1%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-129-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Neurodegenerative disease

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-129-5p is a member of miR-129 family and is located in a fragile site in chromosome 7q32. miR-129-5p has been reported as a tumor suppressor in many types of carcinoma, including breast cancer, colon cancer, osteosarcoma, lung cancer and was also identified as one of the miRNAs that exerted a potent anti-proliferative effect on hepatocellular carcinoma growth. Some researchers have reported that miR-129-5p directly targets DNA (cytosine-5)-methyltransferase 3A (DNMT3A) and functions as a tumor suppressor in glioma. Furthermore, it has been shown that miR-129-5p was downregulated both in gastric cancer tissues and cells. Lower miR-129-5p expression was associated with poor prognosis of gastric cancer patients. In addition, miR-129-5p overexpression reduced cell proliferation and invasion capacities in vitro through targeting ADAM9. Further investigation indicated that miR-129-5p inhibits glucose metabolism in gastric cancer cells.

Besides cancer, miR-129-5p was reported to be associated with Alzheimer’s disease (AD). Expression of miR-129-5p is enriched in developing brain and in neurons, suggesting an important role for miR-129-5p in the maintenance of neuronal function and homeostasis. Moreover, mir-129-5p was identified as a biomarker of heart failure in univentricular heart disease. It was demonstrated that there is an inverse relationship between levels of miR129-5p in circulating microvesicles and the degree of heart failure in pediatric patients with univentricular heart disease.

Summary References (14)

References to miR-129-5p

  • Wang, Shaocheng, et al. "miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer." Pathology-Research and Practice 215.4 (2019): 676-682.
  • Meng, R., et al. "miR-129-5p suppresses breast cancer proliferation by targeting CBX4." Neoplasma 65.4 (2018): 572.
  • Xiao, Guodong, et al. "MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells." Oncotarget 8.61 (2017): 103261.
  • Wu, Qiong, et al. "LncRNA MALAT1 induces colon cancer development by regulating miR‐129‐5p/HMGB1 axis." Journal of cellular physiology 233.9 (2018): 6750-6757.
  • Liu, Ke, et al. "MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142–3p and miR-129–5p." Cell cycle 16.6 (2017): 578-587.
  • Zhang, Yongzhou, et al. "miRNA 129 5p suppresses cell proliferation and invasion in lung cancer by targeting microspherule protein 1, E cadherin and vimentin." Oncology letters 12.6 (2016): 5163-5169.
  • Han, Han, et al. "microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect." Journal of molecular cell biology 8.5 (2016): 400-410.
  • Gu, Xuhui, et al. "MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A." American journal of translational research 10.9 (2018): 2834.
  • Yan, Lei, et al. "MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1." Tumor Biology 39.6 (2017): 1010428317706916.
  • Liu, Qi, et al. "MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9." Biomedicine & Pharmacotherapy 105 (2018): 420-427.
  • Chen, Di, et al. "MicroRNA-129-5p regulates glycolysis and cell proliferation by targeting the glucose transporter SLC2A3 in gastric cancer cells." Frontiers in pharmacology 9 (2018).
  • Patrick, Ellis, et al. "Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease." Molecular neurodegeneration 12.1 (2017): 51.
  • Trujillo-Gonzalez, Isis, et al. "MicroRNA-129-5p is regulated by choline availability and controls EGF receptor synthesis and neurogenesis in the cerebral cortex." The FASEB Journal 33.3 (2018): 3601-3612.
  • Ramachandran, Sweta, et al. "Plasma microvesicle analysis identifies microRNA 129-5p as a biomarker of heart failure in univentricular heart disease." PloS one 12.8 (2017): e0183624.
Related Products Docs